MedPath

The REDUCED-I Pilot Trial: REDucing the Utilization of CEsarean Sections With Induction

Not Applicable
Completed
Conditions
Induced; Birth
Interventions
Drug: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
Registration Number
NCT05037617
Lead Sponsor
University of Calgary
Brief Summary

This pilot project is a randomized controlled trial where induced patients receive an intervention of oxytocin discontinuation once in the active stage of labor (≥6 cm dilation). The intent is to reduce uterine hyperstimulation and fetal distress, therefore, lowering cesarean sections (CS) in first time mothers at term (≥ 37 weeks), with a cephalic presenting singleton fetus, without increasing maternal or neonatal morbidity. If REDUCE-I pilot trial suggests a safe reduction in CS rates and patient satisfaction, application for a multi-centre randomized controlled trial would follow.

Detailed Description

This pilot project is a randomized controlled trial of a proposed intervention to modify management of labor inductions once in the active first stage of labor. The intervention will take place at Foothills Medical Centre (FMC). Randomization will be computer generated, participants will be stratified by need for cervical ripening and randomization will be blocked. Participants will be primiparous women 18 years old or older, at term (≥ 37 weeks) with a cephalic presenting singelton fetus undergoing induction of labor with oxytocin. Once patients are in the active first stage of labor, study medication will be initiated (identical vials of oxytocin or saline prepared by the Alberta Health Services Research Pharmacy). Treatment period will continue until delivery. If the frequency of contractions are reduced to less than 2 in 10 minutes or there has been no change in dilation for 4 hours, then oxytocin can be restarted.

Royal Alexandra Hospital in Edmonton will be used as a contemporaneous non-intervention control site.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
205
Inclusion Criteria
  • pregnant women undergoing induction of labor with oxytocin.
  • Primiparous
  • 18 years old or older
  • at term (≥37 weeks)
  • cephalic presenting
  • singleton fetus
Exclusion Criteria
  • Multiple pregnancies
  • known fetal congenital or chromosomal anomalies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention site (Foothills Medical Centre): Continuation of OxytocinContinuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).Participants in this arm will receive a blinded vial of oxytocin once a patient is found to be \>= 6 cm dilated.
Intervention site (Foothills Medical Centre): Discontinuation of oxytocinContinuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).Participants in this arm will receive a blinded vial of saline solution once a patient is found to be \>= 6 cm dilated.
Primary Outcome Measures
NameTimeMethod
Rate of Cesarean section in laborAt Delivery

Rate of Cesarean section in labor

Occurrence of Uterine HyperstimulationDuring labour, after >=6 cm dilation

Occurrence of \>5 contractions in 10 minutes

Proportion of screened subjects who agree to enroll in the trialDuring screening of potential participants

Proportion of screened subjects who agree to enroll in the trial

Secondary Outcome Measures
NameTimeMethod
Rate of postpartum hemorrhageAt delivery

Rate of postpartum hemorrhage

Rate of postpartum uterine artery/pelvic artery embolizationWithin 28 days of delivery

Rate of postpartum uterine artery/pelvic artery embolization

Rate of postpartum hysterectomyWithin 28 days of delivery

Rate of postpartum hysterectomy

Rate of postpartum maternal intensive care unit (ICU) admissionAt delivery

Rate of postpartum maternal intensive care unit (ICU) admission

Rate of perinatal deathAt delivery

Rate of perinatal death

Rate of moderate or severe asphyxia (Sarnat) or meets criteria for therapeutic coolingAt delivery

Rate of moderate or severe asphyxia (Sarnat) or meets criteria for therapeutic cooling

Rate of neonatal asphyxiaAt delivery

Neonatal asphyxia is defined as intrapartum stillbirth or neonatal death from asphyxia (Perinatal Society of Australia and New Zealand coding) or Neonatal Intensive Care Unit admission and at least two of: a. Apgar score of ≤5 at 10 minutes; b. Mechanical ventilation or chest compressions for resuscitation within 10 minutes; c. Cord pH \< 7.00 (venous or arterial), or arterial base excess ≥ 12 at birth. Rate of neonatal asphyxia for deliveries involving primiparous women in labor, at term (\>= 37 weeks), with a vertex presenting singleton fetus

Rate of neonatal sepsis or suspected sepsisAt delivery

Rate of neonatal sepsis or suspected sepsis

Rate of blood transfusionAt delivery

Rate of blood transfusion

Trial Locations

Locations (1)

University of Calgary

🇨🇦

Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath